Contact Us
Drug Search Results
More Filters [+]

Emricasan

Alternative Names: emricasan, idn-6556
Latest Update: 2024-07-05
Latest Update Note: News Article

Product Description

Mechanisms of Action: CAAP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Histogen
Company Location: San Diego CA 92121
Company CEO: Steven J. Mento
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Emricasan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Liver Cirrhosis|Fatty Liver, Alcoholic|Hepatocellular Carcinoma|Liver Transplant|Hepatitis|Cholestasis|Hypertension, Portal|Hepatitis A|Liver Failure, Acute|Hepatitis C, Chronic|End Stage Liver Disease|Acute-On-Chronic Liver Failure|Hepatic Insufficiency|Hepatitis, Chronic|Liver Cirrhosis, Alcoholic|Type 1 Diabetes

Phase 1: Intestinal Diseases|Kidney Diseases|COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
EMR-COV-PR001

P1

Terminated

COVID-19

2021-05-28

70%
ENCORE-LF

P2

Unknown status

Liver Cirrhosis

2019-08-01

23%
CON-EX-0217

N/A

Terminated

Liver Cirrhosis

2019-07-15

2015-004473-32

P2

Completed

Liver Cirrhosis|Hepatitis, Alcoholic|Hypertension, Portal|Non-alcoholic Steatohepatitis

2019-04-08

Recent News Events

Date

Type

Title

07/05/2024

News Article

 Zika Virus Therapeutics Market size is set to grow by USD 4.17 billion from 2024-2028, Availability of serology kit for qualitative diagnosis of zika virus infection to boost the market growth, Technavio

06/01/2024

PubMed

 The positive feedback loop of the NAT10/Mybbp1a/p53 axis promotes cardiomyocyte ferroptosis to exacerbate cardiac I/R injury.

03/14/2024

PubMed

 Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal.

01/28/2024

PubMed

 Biomaterials Functionalized with Inflammasome Inhibitors-Premises and Perspectives.

07/05/2023

News Article

 Histogen to Explore Strategic Alternatives

04/20/2023

News Article

 Histogen Announces Online Publication in the Journal of Investigative Dermatology

04/20/2023

News Article

 FUJIFILM Wako Chemicals U.S.A. Commercializes CEPT Cocktail for Research-Use iPSC Applications

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions